Acute Myeloid Leukemia
Conditions
Keywords
vaccination, postremission therapy, acute myeloid leukemia, dendritic cells
Brief summary
The aim of this study is to determine the feasibility and safety of an autologous DC immunotherapy in patients with AML of non-favorable risk profile.
Detailed description
Patients ≥ 18 years of either gender with AML of non-favorable risk profile in CR or CRi not being eligible for allogeneic stem cell transplantation will receive as intradermal injections at two different sites up to ten immunotherapies with autologous DCs presenting two leukemia-associated antigens and one CMV antigen conserved in cryomedium over a time span of 26 weeks. Phase I will test the safety and toxicity in a small group of patients (n=6). After at least four vaccinations of three patients, the safety and toxicity data will be presented to the Data safety monitoring board (DSMB). Only after the DSMB has no objectives against the continuation of the trial, further patients will be included into the trial. Again, after three more patients, receiving a minimum of four vaccines, clinical data will be presented to the DSMB, and phase I will be terminated. The decision for continuation of the trial will be done by the DSMB. If there are no objectives by the DSMB, the trial will continue and evaluation will be started in a larger group of patients (n=14). During the phase II trial, safety and toxicity will be evaluated in a larger co-hort of patients). Besides, preliminary assessment of efficacy will be performed including induction of immunological responses to leukemia associated antigens as well as to a viral antigen (CMV), MRD control, time to progression of disease and ECOG performance status.
Interventions
BIOLOGICALDC vaccination for postremission therapy in AML
Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
Sponsors
Ludwig-Maximilians - University of Munich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients male or female, age ≥ 18 years, biological age ≤ 75 years * Patients with AML of non-favorable risk profile or with AML and sole NPM1 mutation and confirmed increase of MRD load as detected by RQ-PCR (in two measurements at least four weeks apart) * CR or CRi after intensive induction chemotherapy (TAD, HAM, sHAM, 3+7 anthracycline + cytarabine regimen, or equivalent) * Negative HIV test, negative hepatitis B and C test * Negative pregnancy test in women of childbearing potential * Ability to understand and willingness to sign a written informed consent
Exclusion criteria
* Patients suitable for allogeneic HSCT (indication for allogeneic HSCT, adequate donor, no contraindication for allogeneic HSCT) * Patients with AML with favorable risk profile: * APL (AML M3) * inv(16), t(16;16), or del(16) as sole anomaly * t(8;21) as sole anomaly * biallelic CEBPA mutation as sole anomaly * NPM1 mutation as sole anomaly, unless with confirmed increase of MRD load * Prior allogeneic HSCT * Anemia (Hb \< 9,0 mg/dl) * Leukopenia (\< 4,0 G/l) * Transfusion refractory thrombocytopenia (\< 30 G/l platelets despite adequate number of transfusions) * Active clinically relevant autoimmune disease * Active immunodeficiency syndromes * Known allergy to GM-CSF, TNF, IFN-γ, IL-4, IL-1 beta, PGE2, R848, Human AB Serum, DMSO, HSA * Continuous therapy with corticosteroids or other immunosuppressive drugs during the trial * Present substance abuse or any other factor that could limit the subject's ability to comply with study procedures * Severe organ dysfunction: * Creatinine \> 2,5 mg/ml * Bilirubin \> 3,0 mg/ml * ALAT and ASAT \> 3 x upper normal limit * Respiratory insufficiency with pO2 \< 60 mmHg * Clinically relevant coronary heart disease of ventricular arrhythmia, congestive heart failure \> grade II NYHA * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study * Simultaneous participation in another clinical trial or participation in any clinical trial involving an investigational medicinal product within 30 days prior to written informed consent for this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| % of grade I/II and grade III/IV toxicities | 30 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Immune responses to applied antigens | 30 weeks |
| Control of minimal residual disease | 30 weeks |
| Time to progression of disease | 30 weeks |
| ECOG performance status | 30 weeks |
Countries
Germany
Outcome results
None listed